Cardiac Imaging

Which Imaging Study Is Best for Suspected Inflammatory Cardiomyopathy?

·
Which Imaging Study Is Best for Suspected Inflammatory Cardiomyopathy?

A 34-year-old patient presents to the emergency department with substernal chest pain and shortness of breath, one week after a flu-like illness. An ECG shows nonspecific T-wave inversions, and the initial troponin is elevated. A coronary CT angiogram was negative for obstructive coronary artery disease, effectively ruling out an acute coronary syndrome. Now, you suspect an inflammatory process like myocarditis. The immediate clinical question is which imaging study to order first to assess myocardial function and structure. This article provides a step-by-step workflow for this specific scenario, grounded in the American College of Radiology (ACR) Appropriateness Criteria. For this presentation, the initial recommended study, `US echocardiography transthoracic resting`, is rated Usually appropriate.

Who Fits This Clinical Scenario?

This guidance applies to patients with a clinical presentation suggestive of an inflammatory cardiomyopathy where ischemic heart disease has already been reasonably excluded. The key inclusion criteria are:

  • New onset of cardiac symptoms such as chest pain, dyspnea, or palpitations.
  • Evidence of myocardial injury (e.g., elevated troponins).
  • A recent viral prodrome or association with a systemic inflammatory or autoimmune condition.
  • Absence of significant coronary artery disease, confirmed by prior invasive coronary angiography or a noninvasive test like coronary CT angiography (CTA).

This workflow is distinct from the workup for other nonischemic cardiomyopathies. It is crucial to differentiate this scenario from presentations where the primary suspicion is a different entity. For example, a patient with a strong family history of sudden cardiac death and a characteristic ECG might be evaluated under the ACR guidelines for suspected hypertrophic cardiomyopathy. Similarly, a patient with signs of right-sided heart failure and low-voltage ECG might better fit the workup for suspected restrictive or infiltrative disease. This article focuses exclusively on the initial imaging step when inflammation is the leading hypothesis.

What Diagnoses Are You Working Up in This Scenario?

When suspecting inflammatory cardiomyopathy, you are evaluating a spectrum of conditions characterized by myocardial inflammation, leading to myocyte injury and dysfunction. The differential diagnosis guides the interpretation of imaging findings.

Myocarditis: This is the most common consideration in this scenario. It is an inflammation of the heart muscle, most frequently caused by viral infections (e.g., Parvovirus B19, Coxsackievirus, SARS-CoV-2). It can present with a wide range of severity, from mild, self-resolving symptoms to fulminant heart failure and cardiogenic shock. Imaging is crucial for assessing the functional consequences, such as reduced ejection fraction and regional wall motion abnormalities.

Cardiac Sarcoidosis: A key, non-infectious inflammatory cause to consider, especially in younger or middle-aged patients presenting with conduction abnormalities (like heart block) or ventricular arrhythmias. Sarcoidosis is a multisystem granulomatous disease, and cardiac involvement carries a poor prognosis if untreated. Imaging helps identify characteristic patterns of inflammation and scarring that can suggest this diagnosis over viral myocarditis.

Giant Cell Myocarditis: While rare, this is a consequential diagnosis that must be considered in any patient with rapidly progressive heart failure. It is an aggressive, often fatal autoimmune condition requiring prompt diagnosis, typically via endomyocardial biopsy, and aggressive immunosuppressive therapy. Initial imaging may show severe, diffuse biventricular dysfunction.

Eosinophilic Myocarditis: This is another uncommon but important cause, often associated with a hypersensitivity drug reaction, parasitic infection, or hypereosinophilic syndromes. The clinical context, including peripheral eosinophilia, is a critical clue. Imaging findings can be similar to other forms of myocarditis.

Why Is US Echocardiography Transthoracic Resting the Recommended Initial Study?

For the initial evaluation of suspected inflammatory cardiomyopathy, the ACR designates `US echocardiography transthoracic resting` as Usually appropriate. This recommendation is based on the modality’s excellent safety profile, widespread availability, and ability to provide immediate, crucial information about cardiac structure and function at the bedside.

A transthoracic echocardiogram (TTE) is the cornerstone of the initial workup. It directly visualizes the heart, allowing for assessment of left and right ventricular size and systolic function (e.g., left ventricular ejection fraction), regional wall motion abnormalities, and valvular function. In the context of myocarditis, TTE may reveal global or regional ventricular dysfunction and, in some cases, a pericardial effusion. These findings, while not specific for inflammation, are critical for risk stratification and guiding immediate management. Importantly, TTE involves no ionizing radiation (0 mSv) and does not require intravenous contrast.

While TTE is the primary starting point, other advanced imaging modalities play a key role, often as a second step.

  • MRI heart function and morphology without and with IV contrast: This study is also rated Usually appropriate. Cardiac MRI (CMR) is the gold standard for noninvasive tissue characterization. It can directly visualize myocardial edema (inflammation), hyperemia, and necrosis/fibrosis using T2-weighted imaging and late gadolinium enhancement (LGE) sequences. While it provides more specific information about inflammation, its lower availability and longer acquisition time make TTE the more practical first-line test. CMR is often the logical next step after an abnormal or equivocal TTE.
  • FDG-PET/CT heart: This modality is rated May be appropriate. It is highly sensitive for detecting active inflammation, particularly in cardiac sarcoidosis. However, it involves significant radiation exposure (10-30 mSv) and requires rigorous patient preparation (a specific diet) to suppress physiologic glucose uptake by the myocardium. It is typically reserved for cases where sarcoidosis is a leading concern or when CMR findings are ambiguous.

Studies like stress echocardiography or coronary arteriography are rated Usually not appropriate in this specific context because the primary question is about myocardial inflammation and function at rest, and ischemic disease has already been excluded.

What’s Next After US Echocardiography Transthoracic Resting? Downstream Workflow

The results of the initial TTE guide the subsequent diagnostic and management pathway. The goal is to confirm the diagnosis, assess prognosis, and direct therapy.

If the TTE is abnormal: Findings such as a newly reduced left ventricular ejection fraction (LVEF), regional wall motion abnormalities, or a significant pericardial effusion strongly support the diagnosis of a cardiomyopathy. The next step is typically a cardiac MRI with gadolinium contrast to confirm inflammation, assess its extent, and look for patterns suggestive of a specific etiology (e.g., the characteristic mid-wall or subepicardial LGE of myocarditis). In hemodynamically unstable patients or those with life-threatening arrhythmias, an endomyocardial biopsy may be pursued concurrently to establish a definitive diagnosis and guide immunosuppressive therapy, especially if giant cell myocarditis or sarcoidosis is suspected.

If the TTE is normal: A normal echocardiogram does not rule out inflammatory cardiomyopathy, particularly if the process is focal or in its early stages. If clinical suspicion remains high (e.g., persistent troponin elevation, concerning symptoms), the next step should be a cardiac MRI. Its superior ability to detect tissue-level changes like edema and focal scarring makes it the definitive noninvasive test in this situation.

If the TTE suggests an alternative diagnosis: Occasionally, the echo may reveal unexpected findings, such as asymmetric septal hypertrophy suggestive of hypertrophic cardiomyopathy or signs of diastolic dysfunction with biatrial enlargement pointing toward a restrictive process. In these cases, the clinical workup should pivot to the appropriate pathway for those conditions, which may involve different imaging sequences, genetic testing, or specific biopsies. You would then refer to the ACR guidance for those sibling scenarios.

Pitfalls to Avoid (and When to Get Help)

Navigating the workup for suspected inflammatory cardiomyopathy requires careful interpretation and a low threshold for escalation. Here are common pitfalls:

  • Anchoring on a normal echocardiogram: Remember that a normal TTE in the face of high clinical suspicion is not a reason to stop the workup. Myocarditis can be focal, and TTE may not detect subtle edema or fibrosis. Proceed to cardiac MRI if the clinical picture is compelling.
  • Misattributing regional wall motion abnormalities: While ischemia has been excluded, the regional wall motion abnormalities in myocarditis can mimic a coronary territory. It is crucial to keep a broad differential and use advanced imaging like CMR to differentiate inflammation from other causes.
  • Delaying definitive diagnosis in severe cases: In a patient with rapidly deteriorating heart function, ventricular arrhythmias, or high-grade heart block, do not delay escalation. If giant cell myocarditis or fulminant sarcoidosis is on the differential, early consultation with an advanced heart failure specialist and consideration for endomyocardial biopsy are critical, as treatment is time-sensitive.

If the patient presents with hemodynamic instability, sustained ventricular tachycardia, or complete heart block, this constitutes a medical emergency. Immediate cardiology consultation is required to coordinate advanced imaging, potential biopsy, and advanced heart failure therapies.

Related ACR Topics and Tools

For a comprehensive overview of imaging choices across all nonischemic cardiomyopathy scenarios, please refer to our parent guide. For other specific clinical questions, the following GigHz resources can help you apply evidence-based imaging strategies.

Frequently Asked Questions

Why is cardiac MRI also rated ‘Usually Appropriate’ but echocardiography is often the first test?

Both are highly valuable, but they answer different questions. Transthoracic echocardiography (TTE) is the best initial test due to its speed, low cost, and wide availability. It provides a rapid assessment of cardiac function, which is critical for immediate clinical management. Cardiac MRI is a more specialized test that provides detailed tissue characterization, allowing for direct visualization of inflammation (edema) and scarring (fibrosis). It’s often used as the second step to confirm the diagnosis after TTE identifies a functional abnormality, or to investigate further when TTE is normal but clinical suspicion remains high.

What if my patient has a contraindication to gadolinium for a follow-up cardiac MRI?

A cardiac MRI without contrast is rated ‘May be appropriate’ by the ACR. While late gadolinium enhancement (LGE) for detecting fibrosis would be omitted, the study can still be highly valuable. Non-contrast sequences, such as T2-weighted imaging and T1/T2 mapping, can detect myocardial edema, which is a key sign of active inflammation. The study can also provide precise, reproducible measurements of ventricular volumes and function.

Is an endomyocardial biopsy still necessary if imaging strongly suggests myocarditis?

For most cases of suspected viral myocarditis with a stable clinical course, imaging findings from cardiac MRI are often sufficient to guide supportive management, and a biopsy is not performed. However, an endomyocardial biopsy remains the gold standard for diagnosis and is crucial in specific high-risk situations: 1) patients with fulminant or rapidly progressive heart failure, 2) patients with life-threatening arrhythmias, or 3) when a specific, treatable diagnosis like giant cell myocarditis or cardiac sarcoidosis is suspected and requires histologic confirmation to initiate aggressive immunosuppressive therapy.

How does the workup change if the patient is hemodynamically unstable?

Hemodynamic instability is a red flag for a fulminant process. While a point-of-care TTE is essential for rapid assessment of ventricular function and to look for complications like tamponade, the priority shifts to stabilization and escalation. This involves immediate consultation with cardiology and critical care. The patient may require mechanical circulatory support (e.g., Impella, ECMO), and the threshold to proceed directly to endomyocardial biopsy is much lower, as a definitive diagnosis is needed urgently to guide potentially life-saving therapies.

Can FDG-PET/CT be used as the initial imaging test instead of echo or MRI?

FDG-PET/CT is generally not the initial test for a broad suspicion of inflammatory cardiomyopathy. It is rated ‘May be appropriate’ and is most valuable when there is a specific suspicion for cardiac sarcoidosis, as it is very sensitive for detecting active granulomatous inflammation. Its disadvantages for initial screening include significant radiation exposure, higher cost, and the need for strict patient dietary preparation. Echocardiography and MRI provide excellent structural and functional data with less radiation and logistical complexity, making them better initial choices.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026